Search

Search articles for

Advanced filters

Published AfterYearMonthDay

Published BeforeYearMonthDay

By Author

By Section

By Issue

Search Results

##search.searchResults.foundPlural##

S-MAPA: bridging the gap in psoriasis severity assessment

Trang Thi Thuy Vu, Chuyen Thi Hong Nguyen, Trung The Van

28-05-2025

https://doi.org/10.4081/dr.2025.10231

665

PDF: 305

HTML: 22
Efficacy of tildrakizumab 200 mg for treating difficult-to-treat patient populations with moderate-to-severe plaque psoriasis

Paolo Dapavo, Matteo Megna, Marina Talamonti

09-08-2024

https://doi.org/10.4081/dr.2024.9999

1776

PDF: 687

HTML: 99
Efficacy and safety of risankizumab in patients with erythrodermic and sub-erythrodermic psoriasis: a case series

Andrea D'Arino, Maria Concetta Fargnoli, Pasquale Frascione, Chiara Assorgi, Annunziata Dattola, Viviana Lora, Matteo Megna, Flavia Pigliacelli, Emanuele Vagnozzi, Diego Orsini

30-07-2025

https://doi.org/10.4081/dr.2025.10379

440

PDF: 305

HTML: 2
Intra-class switch among interleukin-17 inhibitors for the treatment of plaque psoriasis: a single-center experience

Gioele Ghezzi, Luciano Ibba, Luigi Gargiulo, Alessandra Narcisi, Antonio Costanzo, Mario Valenti

12-11-2024

https://doi.org/10.4081/dr.2024.10080

1223

PDF: 689

HTML: 31
Real-world treatment patterns, patient-reported outcomes, and effectiveness of flexible-dosing etanercept in patients with plaque psoriasis in Greece

Dimitris Rigopoulos, Aikaterini Patsatsi, Christina Antoniou, Dimitrios Sotiriadis, Angeliki Roussaki-Schulze, Nadia Boubouchairopoulou, Ioannis Skiadas, Vasillios Tsekouras, Ana Cristina Hernandez Daly

21-11-2022

https://doi.org/10.4081/dr.2022.9265

1552

PDF: 452

HTML: 29
Cost analysis in the management of moderate-to-severe psoriasis: comparison between conventional and biological systemic therapies

Edoardo Mortato, Silvia Baratta, Luca Rubino, Anna Paola De Caro, Francesco Loconsole

19-06-2023

https://doi.org/10.4081/dr.2023.9755

859

PDF: 419

HTML: 20
Anti-interleukin-17 and anti-interleukin-23 biologic drugs for genital psoriasis: a single-center retrospective comparative study

Andrea Cortese, Luigi Gargiulo, Luciano Ibba, Giovanni Fiorillo, Francesco Toso, Carlo Alberto Vignoli, Alessandra Narcisi, Antonio Costanzo, Mario Valenti

19-05-2023

https://doi.org/10.4081/dr.2023.9692

1071

PDF: 550

HTML: 24
Real-world use of dimethyl fumarate in patients with plaque psoriasis: a Delphi-based expert consensus

Martina Burlando, Elena Campione, Aldo Cuccia, Giovanna Malara, Luigi Naldi, Francesca Prignano, Leonardo Zichichi

29-12-2022

https://doi.org/10.4081/dr.2023.9613

1788

PDF: 544

HTML: 77
Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as inflammatory markers in psoriasis: a case-control study

Hao Trong Nguyen, Long Dinh Hoang Vo, Nguyen Nhat Pham

14-07-2022

https://doi.org/10.4081/dr.2022.9516

1682

PDF: 729

HTML: 25
Efficacy and safety of adalimumab biosimilar GP2017 in a 24-month treatment period for plaque psoriasis: real-life experience from Emilia-Romagna centers, Italy

Marco May Lee, Vito Di Lernia, Francesca Peccerillo, Federico Bardazzi, Michela Tabanelli, Michela Ricci, Davide Melandri, Monica Corazza, Francesca Satolli, Andrea Conti

01-07-2025

https://doi.org/10.4081/dr.2025.10315

564

PDF: 278

HTML: 20
Increased serum interleukin-31 levels correlate with pruritus in psoriatic patients: a cross-sectional study in Vietnam

Chuyen Thi Hong Nguyen, Liem Viet Quoc Tran

27-11-2024

https://doi.org/10.4081/dr.2024.10090

793

PDF: 384

HTML: 30
A study on tumor necrosis factor-α single nucleotide polymorphisms and psoriasis vulgaris in Vietnam

Vinh Ngo Minh, Thiên Phúc Lý, Hao Nguyen Trong, Chuong Nguyen Hoang

12-04-2024

https://doi.org/10.4081/dr.2024.9899

970

PDF: 591

HTML: 27
HLA-Cw6 increases the risk of psoriasis and early onset before twenty-seven years of age among the Vietnamese population

Nhi Thi Uyen Pham, Thuong Van Nguyen, Hao Trong Nguyen

16-10-2023

https://doi.org/10.4081/dr.2023.9854

1314

PDF: 530

HTML: 32
Tildrakizumab in the treatment of plaque psoriasis in an HIV+ patient: a case report and literature review of anti-interleukin drugs

Viviana Lora, Dario Graceffa, Monia Di Prete, Carlo Cota

11-11-2024

https://doi.org/10.4081/dr.2024.10140

1014

PDF: 536

SUPPLEMENTARY MATERIAL: 160

HTML: 18
Increased plasma lipocalin-2 levels correlate with disease severity and may be a marker of acute inflammatory response in patients with psoriasis

Chuyen Thi Hong Nguyen, Oanh Phan Tram Nguyen

21-11-2022

https://doi.org/10.4081/dr.2022.9469

1321

PDF: 553

HTML: 37
The suitability of mesenchymal stem cells for treating immune-mediated inflammatory skin diseases: a systematic review

Elena Pezzolo, Sara Di Leo, Paola Miceli, Alvise Sernicola, Luigi Naldi

01-07-2025

https://doi.org/10.4081/dr.2025.10112

892

PDF: 666

HTML: 27
Severe relapse of generalized psoriasis in a young patient with a Löfgren syndrome history

Ermira Ziçishti, Migena Vargu, Sabina Dedej, Eriselda Kurushi, Valbona Zenelaj, Ermira Vasili

13-03-2025

https://doi.org/10.4081/dr.2025.10021

475

PDF: 318

HTML: 11
Guselkumab for the treatment of severe plaque psoriasis in a schizophrenia patient

Nicoletta Bernardini, Nevena Skroza, Elisabeth Prevete, Federica Marraffa, Ilaria Proietti, Ersilia Tolino, Alessandra Mambrin, Giovanni Rossi, Salvatore Volpe, Giuseppe Bersani, Concetta Potenza

23-11-2022

https://doi.org/10.4081/dr.2022.9476

1487

PDF: 495

HTML: 29
Seven cancer patients receiving guselkumab for treatment of moderate-to-severe psoriasis

Luca Mastorino, Niccolò Siliquini, Gianluca Avallone, Michela Ortoncelli, Pietro Quaglino, Paolo Dapavo, Simone Ribero

17-03-2022

https://doi.org/10.4081/dr.2022.9282

1173

PDF: 830

HTML: 44
Mycobacterium kansasii infection in a psoriasis patient treated with adalimumab and switch to apremilast: First report and literature review

Alexandra Maria Giovanna Brunasso, Sanja Javor, Emanuele Pontali, Simona Sola, Cesare Massone

29-07-2021

https://doi.org/10.4081/dr.2021.8797

3067

PDF: 651

HTML: 13
Lentiginous eruption in resolving psoriasis plaques during treatment with ixekizumab: a case report and review of the literature

Pablo Santa María, Fernando Valenzuela, Claudia Morales, Raul De la Fuente, Roberto Cullen

11-10-2017

https://doi.org/10.4081/dr.2017.7079

1394

PDF: 667

HTML: 144
Dimethyl fumarate as a safe and effective therapy for recalcitrant psoriasis in comorbid patients

Martina Burlando, Mattia Fabio Molle, Emanuele Cozzani, Aurora Parodi

14-03-2022

https://doi.org/10.4081/dr.2022.9091

2637

PDF: 637

HTML: 9
Long term efficacy, safety, and tolerability of tildrakizumab in epileptic patient with psoriasis and eczema

Nicoletta Bernardini, Nevena Skroza, Giovanni Rossi, Alessandra Mambrin, Ersilia Tolino, Federica Marraffa, Martina Caviglia, Antonio Di Guardo, Salvatore Volpe, Ilaria Proietti, Concetta Potenza

21-11-2022

https://doi.org/10.4081/dr.2022.9447

1316

PDF: 407

HTML: 46
Exacerbation of generalized plaque psoriasis after tuberculin test

Alberto Corrà, Lavinia Quintarelli, Alice Verdelli, Walter Volpi, Marzia Caproni

28-07-2021

https://doi.org/10.4081/dr.2021.9019

3193

PDF: 508

HTML: 235
Does the response to bimekizumab vary according to previous therapy with methotrexate versus cyclosporine?

Ilaria Salvi, Alexandra M. G. Brunasso, Franco Castelli, Andrea Michelerio, Paolo Pella, Marco Rubatto, Paolo Dapavo, Emanuele Cozzani, Martina Burlando

20-03-2026

https://doi.org/10.4081/dr.2026.10236

253

PDF: 199

1 - 25 of 39 items 1 2 > >>

Search

Search Results

S-MAPA: bridging the gap in psoriasis severity assessment

Efficacy of tildrakizumab 200 mg for treating difficult-to-treat patient populations with moderate-to-severe plaque psoriasis

Efficacy and safety of risankizumab in patients with erythrodermic and sub-erythrodermic psoriasis: a case series

Intra-class switch among interleukin-17 inhibitors for the treatment of plaque psoriasis: a single-center experience

Real-world treatment patterns, patient-reported outcomes, and effectiveness of flexible-dosing etanercept in patients with plaque psoriasis in Greece

Cost analysis in the management of moderate-to-severe psoriasis: comparison between conventional and biological systemic therapies

Anti-interleukin-17 and anti-interleukin-23 biologic drugs for genital psoriasis: a single-center retrospective comparative study

Real-world use of dimethyl fumarate in patients with plaque psoriasis: a Delphi-based expert consensus

Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as inflammatory markers in psoriasis: a case-control study

Efficacy and safety of adalimumab biosimilar GP2017 in a 24-month treatment period for plaque psoriasis: real-life experience from Emilia-Romagna centers, Italy

Increased serum interleukin-31 levels correlate with pruritus in psoriatic patients: a cross-sectional study in Vietnam

A study on tumor necrosis factor-α single nucleotide polymorphisms and psoriasis vulgaris in Vietnam

HLA-Cw6 increases the risk of psoriasis and early onset before twenty-seven years of age among the Vietnamese population

Tildrakizumab in the treatment of plaque psoriasis in an HIV+ patient: a case report and literature review of anti-interleukin drugs

Increased plasma lipocalin-2 levels correlate with disease severity and may be a marker of acute inflammatory response in patients with psoriasis

The suitability of mesenchymal stem cells for treating immune-mediated inflammatory skin diseases: a systematic review

Severe relapse of generalized psoriasis in a young patient with a Löfgren syndrome history

Guselkumab for the treatment of severe plaque psoriasis in a schizophrenia patient

Seven cancer patients receiving guselkumab for treatment of moderate-to-severe psoriasis

Mycobacterium kansasii infection in a psoriasis patient treated with adalimumab and switch to apremilast: First report and literature review

Lentiginous eruption in resolving psoriasis plaques during treatment with ixekizumab: a case report and review of the literature

Dimethyl fumarate as a safe and effective therapy for recalcitrant psoriasis in comorbid patients

Long term efficacy, safety, and tolerability of tildrakizumab in epileptic patient with psoriasis and eczema

Exacerbation of generalized plaque psoriasis after tuberculin test

Does the response to bimekizumab vary according to previous therapy with methotrexate versus cyclosporine?

authors

reviewers

Categories

indexing

dermatopathology